ABSTRACT
A series of nicotinamide N-oxides was synthesized and shown to be novel, potent, and selective antagonists of the CXCR2 receptor. Furthermore, these compounds showed significant functional activity against GRO-alpha-driven human neutrophil chemotaxis. Compounds of this class may be useful for the treatment of inflammatory, auto-immune, and allergic disorders.
Subject(s)
Chemokines, CXC , Chemotactic Factors/metabolism , Chemotaxis/drug effects , Growth Substances/metabolism , Intercellular Signaling Peptides and Proteins , Interleukin-8/metabolism , Niacinamide/analogs & derivatives , Niacinamide/pharmacology , Receptors, Interleukin-8B/antagonists & inhibitors , Autoimmune Diseases/drug therapy , Binding Sites/physiology , Chemokine CXCL1 , Chemotaxis/physiology , Humans , Hypersensitivity/drug therapy , Inflammation/drug therapy , Inhibitory Concentration 50 , Neutrophils/physiology , Niacinamide/chemical synthesis , Protein Binding/physiology , Structure-Activity RelationshipABSTRACT
One of the most difficult issues a case manager has to deal with is how to stay knowledgeable and current in the face of rapidly changing medical advances. As treatment protocols for diseases change, so must the case management plans for clients. In the case of HIV/AIDS, this is especially true. This article examines the many opportunities case managers have to make an impact on clients' lives and long-term outcomes. As case managers increase their knowledge of disease processes and treatment protocols, they assist their clients in becoming empowered and becoming partners in their treatment plans, at the same time showing them how they can once again gain control of their lives.
